新闻 > 正文

美敦力完成惠柯收购 将优先产品发展

2015-03-17 11:22:45 来源:生物谷

2015年3月13日 讯/生物谷BIOON/ --美敦力公司完成499亿美元收购惠柯的交易刚一个多月的时间,新的整合公司正在向着雄心勃勃的计划努力。美敦力的首席集成官Geoff Martha说该公司首要的战略是开发能够支持创新疗法的设备,最终能节约成本和使医疗保健更有效。

美敦力在市场开发上是一个行业领袖,但是惠柯在用手术工具和医院供需品满足临床需求方面拥有丰富的经验。美敦力的规模和经验结合惠柯已有的业务将推动更快的增长并增加合并后公司的全球足迹。Geoff讲到,"对两个公司来讲,他们的核心是产品发展,这是两个公司的心脏和灵魂,我们相信整合之后将能更加加快这一进程。"

但美敦力也承诺在今后的三年中要实现8500万美元的盈余,而该战略中的一部分是削减业务、房地产、财务和人力资源。整合后的第一年的目标是消除冗余,后两年将主要集中在"持续的产能改变"。与此同时,美敦力正在专注于整个其与惠柯的技术平台并开发新产品并推动已有的设备。Martha特别提到的是该公司近期刚获批的用于外周血管疾病的药物涂层球囊将诸位主要的增长点。进一步讲,整合后的公司将优先考虑低风险和合适回报的项目。

"最大的挑战之一是你有很多闪光点值得追逐。销售和研发团队在会议结束后关于这些想法都非常兴奋。但你必须要专注地做事。"Martha说,"我们面临的挑战之一就是优先考虑这些机会并保持专注。"

Martha表示,公司对收购惠柯的交易进展到目前为止非常满意。作为美敦力战略和业务发展高级副总裁和首席集成官,Martha将他多年的并购经验带到了工作中。他表示,他曾见过其它的公司整合有这很大的"企业文化问题"。两家公司在表明上可能貌似很好,但将它们放在一起时,它们就像油和水。他表示新的美敦力已有6周的时间,他觉得有一个非常好的基础建设,有同样的文化。他说:"当你有这样的基础时,你可以迎接挑战。"

Medtronic prioritizes product development post-Covidien deal close

A little more than a month after Medtronic ($MDT) closed its $49.9 billion purchase of Covidien, the combined company is forging ahead with ambitious plans for growth. And as Medtronic's chief Integration officer, Geoff Martha, told FierceMedicalDevices, the company's "first and foremost strategy" involves developing new devices to support innovative therapies, ultimately cutting costs and making healthcare more efficient.

Medtronic is an industry leader in market development, but Covidien is experienced at addressing unmet clinical need with surgical tools and hospital offerings. Minneapolis, MN-based Medtronic's scale and expertise, combined with Covidien's existing commitments to emerging markets and R&D, will drive faster growth and increase the combined company's global footprint, Martha said.

"For both companies, their DNA is product development. That's the heart and soul of both companies, and together we think we can accelerate the process," he said. But Medtronic is also aiming for $850 million in savings over the next three years, and part of that strategy involves making cuts in operations, real estate, finance and human resources. The first year of the combined company will be aimed toward eliminating redundancies, and the next two years of the integration will be focused on "sustained productivity changes," Martha said.

In the meantime, Medtronic is focusing on combining its technological platforms with Covidien's to develop new products and drum up existing devices. In particular, Martha mentioned the company's recently approved drug-coated balloon for peripheral vascular disease as a driver of growth. Moving forward, the combined company will prioritize devices with "lower risk and the right return profile," he said.

"One of the biggest challenges is, you have lots of shiny objects you can chase. Sales teams and R&D teams walk out of meetings excited about all the ideas. But you have to focus," Martha said. "One of our biggest challenges is prioritizing these opportunities and maintaining focus."

Still, Martha said the company is pleased with how the deal has progressed thus far. Martha, who brings years of M&A experience to his role as Medtronic's Senior Vice President of Strategy and Business Development and Chief Integration Officer, said he has seen other integrations where companies have "big culture problems." The two companies look good on paper, but when you put them together "it's like oil and water," Martha said.

"As we sit here today, 6 weeks into the new Medtronic, we feel like we have a really good base that we're building on. We have a cultural alignment," he said. "When you have that kind of foundation, you can deal with the challenges."

hr@yaochenwd.com.cn
010-59444760